Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 2775 of 3173 entries
View as:

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers.

Phase: N/A Priority: Normal
NCT ID: NCT06870487 Org: User:
Start: 05/08/25 End: 04/11/29 Due: 04/11/30

A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.

Phase: N/A Priority: Normal
NCT ID: NCT05689164 Org: User:
Start: 03/13/23 End: 08/29/25 Due: 08/29/26

A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®

Phase: N/A Priority: Normal
NCT ID: NCT00356421 Org: User:
Start: 11/30/06 End: 06/30/08 Due: 06/30/09

Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.

Phase: N/A Priority: Normal
NCT ID: NCT01026038 Org: User:
Start: 04/30/10 End: 11/30/10 Due: 11/30/11

Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children

Phase: N/A Priority: Normal
NCT ID: NCT00163618 Org: User:
Start: 06/30/05 End: 07/31/06 Due: 07/31/07

A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT00982657 Org: User:
Start: 09/30/09 End: 03/31/14 Due: 03/31/15

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Phase: N/A Priority: Normal
NCT ID: NCT06758401 Org: User:
Start: 05/04/25 End: 03/01/29 Due: 03/01/30

Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

Phase: N/A Priority: Normal
NCT ID: NCT06899204 Org: User:
Start: 06/30/25 End: 08/31/26 Due: 08/31/27

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Phase: N/A Priority: Normal
NCT ID: NCT06447662 Org: User:
Start: 06/27/24 End: 08/26/28 Due: 08/26/29

Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects

Phase: N/A Priority: Normal
NCT ID: NCT00868530 Org: User:
Start: 09/30/08 End: 12/31/09 Due: 12/31/10

Long-Term Effectiveness And Safety Of CP-690,550 For The Treatment Of Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00413699 Org: User:
Start: 02/05/07 End: 10/26/17 Due: 10/26/18

A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure

Phase: N/A Priority: Normal
NCT ID: NCT00422461 Org: User:
Start: 02/27/07 End: 01/28/08 Due: 01/28/09

PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01441414 Org: User:
Start: 11/21/11 End: 03/27/14 Due: 03/27/15

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04181788 Org: User:
Start: 03/18/20 End: 04/30/25 Due: 04/30/26

A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

Phase: N/A Priority: Normal
NCT ID: NCT05886777 Org: User:
Start: 06/05/23 End: 01/01/24 Due: 01/01/25

This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00932126 Org: User:
Start: 09/30/09 End: 12/31/11 Due: 12/31/12

A Study Comparing PF-06273340 Immediate Release Tablet, PF-06273340 Modified Release Tablets To PF-06273340 Oral Solution In The Fasted State. This Study Will Also Compare PF-06273340 Modified Release Tablets In Fasted And Fed State

Phase: N/A Priority: Normal
NCT ID: NCT01706796 Org: User:
Start: 11/30/12 End: 01/31/13 Due: 01/31/14

Pharmacokinetics and Safety of Desvenlafaxine in Korean Healthy Subjects Following Single and Multiple Oral Doses of Desvenlafaxine Succinate Sustained Release Tablet

Phase: N/A Priority: Normal
NCT ID: NCT01443208 Org: User:
Start: 11/30/11 End: 12/31/11 Due: 12/31/12

An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System

Phase: N/A Priority: Normal
NCT ID: NCT00806351 Org: User:
Start: 08/31/09 End: 10/31/11 Due: 10/31/12

Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy.

Phase: N/A Priority: Normal
NCT ID: NCT00370565 Org: User:
Start: 06/30/99 End: 09/30/00 Due: 09/30/01

A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.

Phase: N/A Priority: Normal
NCT ID: NCT03329092 Org: User:
Start: 04/05/18 End: 02/23/23 Due: 02/23/24

Pediatric Pharmacokinetics And Safety Study Of Moxidectin

Phase: N/A Priority: Normal
NCT ID: NCT01035619 Org: User:
Start: 04/30/11 End: 04/30/11 Due: 04/30/12

Lorlatinib Renal Impairment Study

Phase: N/A Priority: Normal
NCT ID: NCT03542305 Org: User:
Start: 08/23/18 End: 02/20/20 Due: 02/20/21

A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD

Phase: N/A Priority: Normal
NCT ID: NCT03539601 Org: User:
Start: 04/27/18 End: 12/11/20 Due: 12/11/21

An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents

Phase: N/A Priority: Normal
NCT ID: NCT03405818 Org: User:
Start: 10/22/15 End: 07/27/17 Due: 07/27/18